3717-88-2 Usage
Description
Flavoxate hydrochloride, also known as ChEBI, is the hydrochloride salt of flavoxate. It is a crystalline solid that possesses unique chemical properties, making it a valuable compound in various applications.
Uses
Used in Pharmaceutical Industry:
Flavoxate hydrochloride is used as an antispasmodic agent for the treatment of urinary incontinence. It helps to relieve muscle spasms in the urinary tract, providing relief from the symptoms of incontinence.
Used in Medical Applications:
Flavoxate hydrochloride is used as a phosphodiesterase inhibitor, which plays a role in the regulation of smooth muscle tone. By inhibiting phosphodiesterase, it can help to relax smooth muscles, particularly in the urinary tract, providing relief from urinary disorders and improving overall bladder function.
Therapeutic Function
Spasmolytic
Veterinary Drugs and Treatments
Flovoxate may be considered for treating dogs with detrusor hyperspasticity
(hyperactive bladder, urge incontinence).
Check Digit Verification of cas no
The CAS Registry Mumber 3717-88-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,7,1 and 7 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 3717-88:
(6*3)+(5*7)+(4*1)+(3*7)+(2*8)+(1*8)=102
102 % 10 = 2
So 3717-88-2 is a valid CAS Registry Number.
InChI:InChI=1/C24H25NO4.ClH/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25;/h2,4-5,8-12H,3,6-7,13-16H2,1H3;1H
3717-88-2Relevant articles and documents
METHODS FOR TREATING CHRONIC FATIGUE SYNDROME AND MYALGIC ENCEPHALOMYELITIS
-
, (2021/03/13)
In one aspect the invention relates to a method of treatment selected from the group consisting of: (a) treating a symptom such as pain in a subject identified or diagnosed as having Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS); (b) treating a symptom such as pain in a subject having dysfunctional TRPM3 ion channel activity; (c) restoring NK cell function in a subject having dysfunctional TRPM3 ion channel activity; and (d) restoring calcium homeostasis in a subject having dysfunctional TRPM3 ion channel activity. The method comprises the step of administering to the subject a therapeutically effective amount of at least one therapeutic compound selected from the group consisting of: (i) an opioid receptor antagonist; (ii) an opioid antagonist; and (iii) a therapeutic compound that restores TRPM3 ion channel activity. In some embodiments the therapeutic compound is naltrexone hydrochloride.